Who is sponsoring QPX9003?

QPX9003 is sponsored by Qpex Biopharma, Inc..

What condition does QPX9003 study?

QPX9003 studies Bacterial Infections.

What drugs are being tested in QPX9003?

Interventions: QPX9003 for IV Infusion, Placebo for IV infusion.

What is the status of QPX9003?

QPX9003 is currently COMPLETED.

Last reviewed 2022-10-10 · How we verify

SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers

NCT04808414 PHASE1 COMPLETED

The worldwide spread of resistance to antibiotics among gram-negative bacteria, particularly members of the ESKAPE group of pathogens, has resulted in a crisis in the treatment of hospital acquired infections. In particular, the presence of multi-drug resistant Acinetobacter baumannii and Pseudomonas aeruginosa in hospitals around the world poses a considerable threat. .

Details

Lead sponsor	Qpex Biopharma, Inc.
Phase	PHASE1
Status	COMPLETED
Enrolment	104
Start date	Thu Jun 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jul 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Bacterial Infections

Interventions

QPX9003 for IV Infusion
Placebo for IV infusion

Countries

United States